Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-07-26
Target enrollment:
Participant gender:
Summary
The proposed study is a prospective, single-center, single-arm and open-ended phase II study
in patients over the age of 18 with previously untreated mantle cell lymphoma(MCL). The
primary objective of this study is to explore the safety and efficacy of a new chemo-free
treatment pattern zanubrutinib-rituximab(ZR) in newly diagnosed MCL.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University